US FDA Chief Favors LDT Approach In Bucshon-DeGette Bill

FDA Commissioner Scott Gottlieb told Reps. Larry Bucshon, R-Ind. and Diana DeGette, D-Colo., that he favors their approach to regulating laboratory developed tests, as spelled out in their draft Diagnostics Accuracy and Innovation Act bill released last spring. The traditional device approval process is a "poor fit" for LDTs, he added.

PCR strip test tubes and micropipette in genetics laboratory. Toned photo

The traditional device approval process is a "poor fit" for laboratory developed tests, FDA Commissioner Scott Gottlieb told Congress at a Nov. 30 check-in hearing on implementation the 21st Century Cures Act. Gottlieb added that FDA staff will continue to offer technical assistance to help refine a "Diagnostics Accuracy and Innovation Act" defining new regulations for LDTs. His comments came at a hearing before the House Energy and Commerce Health Subcommittee.

"There is an opportunity to fashion a new regulatory framework, through the appropriate legislation, that will be a better fit for the kind of technology we're talking about here," Gottlieb...

More from In Vitro Diagnostics

More from Diagnostics